By Denny Jacob
Hims & Hers Health shares tumbled after a leading competitor said a shortage of its weight-loss treatments has been resolved, raising questions about the company's prospects in the space.
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
Drugmaker Novo Nordisk said that the Food and Drug Administration determined that the shortage of Wegovy and Ozempic, the company's blockbuster obesity and diabetes drugs, has been resolved. It added that the regulator's assessment confirmed that the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.S. demand.
The news appears to have alarmed Hims' investors, given the company's weight-loss offering filled a void left by a mismatch in supply and demand. The company last year began offering access to compounded semaglutide, a version of the active ingredient in Novo Nordisk's Wegovy and Ozempic drugs, at a far lower price than those branded drugs.
The FDA allows semaglutide to be compounded because it is considered to be in short supply. The regulator on Friday said it doesn't intend to take action against compounders to avoid unnecessary disruption to patient treatment.
Hims, a telehealth-consultation platform, has indicated it will stick with its weight-loss offerings even if GLP-1 drugs are taken off the FDA's shortage list. The company also focuses on treatments for sexual health, hair loss and mental health, among others.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 21, 2025 11:01 ET (16:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。